DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/gpxpfk/2009_united) has announced the addition of Frost & Sullivan's new report "2009 United States Oncology Drug Delivery Patterns, Preferences, and Opportunities - Volume 1: Oncologist and Infusion Nurse Perspectives" to their offering.
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. This customer research was completed to understand trends, dynamics, and parameters specific to the delivery of drugs to cancer patients; identify physicians prescribing trends relative to delivery considerations; understand the role of reimbursement in a physician's choice of drug delivery; and determine product attributes relative to delivery that are considered important by patients and oncologists. This is important for biotechnology products used in this area as companies seek to design new products and evaluate new opportunities for targeted therapies and other cancer treatments.
Potential Trends in Usage:
- There is potential for the share of oral medication to increase based on the higher proportion of preference for this method.
- In the next 12-24 months, a significant proportion of oncologists expect oral prescriptions to increase, with IV infusion and IV injection the next leading delivery categories for increased prescription.
- Intravenous injections, intravenous infusions and oral medications are the most prescribed classes of drugs.
- For Cytotoxic therapies, intravenous injection is the most preferred oncology drug delivery mode. Across hormone and targeted therapies, Oral is most preferred.
- Oncologists are most satisfied with intravenous injections and oral drug delivery modes.
- Oral delivery is the leading desired method for new drug development from oncologists.
- After published clinical data, Practice is Reimbursed was the second leading reason for drug delivery device selection from oncologists.
- In the next 12-24 months, infusion nurses anticipate a significant amount of change in the oncology drug delivery modes they will administer. The top three modes that are anticipated to increase include: oral, external infusion pump, and implant.
- Infusion nurses most frequently administer intravenous infusion, intravenous injection, and oral modes of oncology drug delivery.
- Infusion nurses are most satisfied with intravenous infusion. They are also satisfied with intravenous injections and external infusion pumps.
- Oral is the most desired method for new drug development from infusion nurses. Infusion nurses desired usage of implant and implantable infusion pump for new products at a significantly higher rate than oncologists.
For more information visit http://www.researchandmarkets.com/research/gpxpfk/2009_united
Source: Frost & Sullivan
Source: Research and Markets